These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19114463)

  • 1. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.
    Zhao R; Kalvass JC; Yanni SB; Bridges AS; Pollack GM
    Drug Metab Dispos; 2009 Mar; 37(3):529-35. PubMed ID: 19114463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
    Tahara H; Kusuhara H; Fuse E; Sugiyama Y
    Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake and efflux of the peptidic delta-opioid receptor agonist.
    Dagenais C; Ducharme J; Pollack GM
    Neurosci Lett; 2001 Apr; 301(3):155-8. PubMed ID: 11257421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.
    Tateishi T; Miura M; Suzuki T; Uno T
    Br J Clin Pharmacol; 2008 May; 65(5):693-700. PubMed ID: 18294330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
    Drescher S; Schaeffeler E; Hitzl M; Hofmann U; Schwab M; Brinkmann U; Eichelbaum M; Fromm MF
    Br J Clin Pharmacol; 2002 May; 53(5):526-34. PubMed ID: 11994059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.
    Sakugawa T; Miura M; Hokama N; Suzuki T; Tateishi T; Uno T
    Br J Clin Pharmacol; 2009 May; 67(5):535-40. PubMed ID: 19552748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
    Bedada SK; Appani R; Boga PK
    Drug Dev Ind Pharm; 2017 Jun; 43(6):932-938. PubMed ID: 28102715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.
    Zhao R; Kalvass JC; Pollack GM
    Pharm Res; 2009 Jul; 26(7):1657-64. PubMed ID: 19384470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.
    Turncliff RZ; Hoffmaster KA; Kalvass JC; Pollack GM; Brouwer KL
    J Pharmacol Exp Ther; 2006 Aug; 318(2):881-9. PubMed ID: 16690724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport characteristics of fexofenadine in the Caco-2 cell model.
    Petri N; Tannergren C; Rungstad D; Lennernäs H
    Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
    Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
    Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
    Pinto L; Moreira FL; Nardotto GHB; Cavalli RC; Moisés ECD; Duarte G; Lanchote VL
    Pharm Res; 2020 Jun; 37(7):131. PubMed ID: 32557079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.
    Neerati P; Bedada SK
    Pharmacol Rep; 2015 Apr; 67(2):339-44. PubMed ID: 25712660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
    Pinto L; Bapat P; de Lima Moreira F; Lubetsky A; de Carvalho Cavalli R; Berger H; Lanchote VL; Koren G
    Pharm Res; 2021 Apr; 38(4):647-655. PubMed ID: 33825113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
    Kim KA; Park PW; Park JY
    Eur J Clin Pharmacol; 2009 Jun; 65(6):609-14. PubMed ID: 19221726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.
    Kim KA; Park JY
    Eur J Clin Pharmacol; 2010 Jul; 66(7):721-5. PubMed ID: 20306185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transporter-mediated intestinal absorption of fexofenadine in rats.
    Kikuchi A; Nozawa T; Wakasawa T; Maeda T; Tamai I
    Drug Metab Pharmacokinet; 2006 Aug; 21(4):308-14. PubMed ID: 16946558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y; Miura M; Yasui-Furukori N; Kojima M; Uno T
    Br J Clin Pharmacol; 2012 Mar; 73(3):478-81. PubMed ID: 21950458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
    Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
    Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.